Brief: Aura Biosciences Reports Third Quarter 2021 Financial Results And Provides Clinical Development And Operational Highlights
24/11/2021 21:09
Nov 24 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS
AND PROVIDES CLINICAL DEVELOPMENT AND OPERATIONAL HIGHLIGHTS
* AURA BIOSCIENCES INC - BELIEVES CURRENT CASH AND CASH
EQUIVALENTS ARE SUFFICIENT TO FUND COMPANY'S OPERATIONS INTO
2024
* AURA BIOSCIENCES INC - QTRLY NET LOSS PER SHARE
ATTRIBUTABLE TO
COMMON STOCKHOLDERS, BASIC AND DILUTED $28.33
Source text for Eikon: ID:nBw1prwMfa
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs